Principal Modeling & Simulation Specialist

Be the new Principal Modeling & Simulation Specialist In a biotech company bonding to discover, design and develop innovative peptide-based medicines. Currently, we are looking for a principal modeling and simulation specialist with extensive experience in modeling and simulation, a strong background in pharmacokinetics (PK) and pharmacodynamics (PD), and a deep understanding of biology, physiology, and regulatory mechanisms. If this sounds like you, and you are ready to take on a broad area of responsibilities with an independent attitude, you are a match for us. Modeling & Simulation is a new Department within Pharmacokinetics, Immunogenicity and Bioanalytical Sciences under Research and Non-clinical Development. The Department will have the responsibilities to support clinical development projects and late phase research projects by setting the direction and drive execution of translational PK and PK/PD strategies. In addition, the Department will be responsible for building mathematical models and performing human PK and PD simulations to guide non-clinical and clinical study designs as well as regulatory discussions. You will report directly to the Head of Modeling and Simulation. The position is based in our headquarter in Søborg, Copenhagen area. Responsibilities Develop and implement mathematical models to simulate human pharmacokinetics (PK) and pharmacodynamics (PD) for non-clinical and clinical study designs. Perform human PK and PD simulations to support regulatory interactions and submissions. Collaborate with cross-functional teams to integrate modeling and simulation insights into clinical development and late-phase research projects. Ensure the accuracy and reliability of simulation models through rigorous testing and validation. Stay current with advancements in modeling and simulation technologies and methodologies, incorporating best practices into projects. Prepare and present detailed reports and visualizations of simulation outcomes to stakeholders. Oversee outsourced modeling and simulation activities, ensuring they meet quality standards and project requirements. Support the development and execution of translational PK and PK/PD strategies. Candidate profile MSc degree or PhD within Pharmaceutical, Medical, Engineering, Statistical or Mathematical sciences or equivalent. At least 5 years of experience in modeling and simulation within pharma or biotech industry and a proven track record of leading successful projects. Comprehensive knowledge of pharmacokinetics (PK), including the processes of absorption, distribution, metabolism, and excretion of drugs. In-depth understanding of biology, physiology, and various regulatory mechanisms. Proficiency in simulation software (e.g. Phoenix WNL/NLME or similar) Strong analytical and problem-solving skills, with the ability to interpret complex data and develop accurate models. Excellent communication and presentation skills, capable of conveying technical information to non-technical stakeholders. Ability to work collaboratively in a multidisciplinary environment and manage multiple projects simultaneously. Bonding to innovate Our employees are fundamental to our success, and we continue to be able to attract and retain people with vast experience and talent. We have a unique culture, characterized by excellent teamwork and strong engagement across the organization. Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other. We bond as a result of our entrepreneurial culture where our people are encouraged to pursue their ideas and turn them into reality. We are curious about each other’s knowledge and expertise. We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation. Zealand Pharma is a place where everyone is heard and contributes to the success, we all want to experience. The Zealand Pharma DNA builds on four values: (1) We are bold, (2) We empower people, (3) We work as one team, and (4) We can be trusted. Let’s bond and be bold We offer a combined compensation package which includes a base salary, pension, bonus, and a possibility to join our employee share program. We care about our employees’ well-being and offer health insurance, use of massage, fitness, and a range of social clubs and activities To find out more about working at Zealand, visit https://www.zealandpharma.com/careers/zealand-as-a-workplace/ Interested? Please apply no later than 30th of April, 2025, or as soon as possible. The applications will be reviewed as they come in. For further information, please contact Carsten Boye Knudsen, CKnudsen@zealandpharma.com / 45 5060 3614 About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a Danish biotechnology company on a mission to change lives with next generation peptide medicines. In our effort to reach our goals bonding is at the core of everything we do. Let it be discovering and developing the best new peptide drugs for patients, engaging with partners or connecting with each other. This has led to more than 10 drug candidates invented by Zealand having advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Additionally, the portfolio includes clinical license collaboration with Boehringer Ingelheim. Zealand is based in Copenhagen (Søborg), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or bond with us through LinkedIn. Since our founding in 1998, Zealand Pharma has built a core expertise in the discovery, design, and development of therapeutic peptides. This expertise has led to an R&D pipeline of innovative investigational candidates designed to address a broad range of disease areas. We have four therapeutic focus areas: obesity, rare diseases, chronic inflammation, and type 1 diabetes. In obesity, our peptide capabilities place us in a unique position to address a vast global health challenge and positively impact hundreds of millions of lives. Within rare diseases, we have a long-standing commitment to deliver new treatments to patients living with congenital hyperinsulinism and short bowel syndrome. For chronic inflammatory diseases, we are progressing peptide programs focused on high-profile targets shown to be difficult to address with small molecules and antibodies. For type 1 diabetes, we aspire to change the management of this disease. Our strategy is to pursue global co-development and commercialization partnerships that complement and extend our capabilities across the value chain to deliver new peptide therapies to people who need them.